Generation Bio Stock News

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announ

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announce

Generation Bio (NASDAQ:GBIO) had its price objective lowered by Needham & Company LLC from $50.00 to $27.00 in a research report released on Wednesday morning, Analyst Ratings Network reports. Needham & Company LLC currently has a buy rating on the stock. Other equities analysts have also recently issued research reports about the stock. JMP Securities []

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.

JPMorgan Chase & Co. downgraded shares of Generation Bio (NASDAQ:GBIO) from an overweight rating to a neutral rating in a research note published on Wednesday, The Fly reports. GBIO has been the topic of several other reports. Zacks Investment Research upgraded shares of Generation Bio from a sell rating to a hold rating in a []

Generation Bio (NASDAQ:GBIO) had its price objective reduced by equities researchers at JMP Securities from $40.00 to $10.00 in a note issued to investors on Wednesday, Benzinga reports. The firm currently has a market outperform rating on the stock. JMP Securities price target indicates a potential upside of 66.94% from the stocks current price. A []

Generation Bio Co (NASDAQ: GBIO ) provided an update on factor VIII expression from a series of mouse and companion non-human primate (NHP) studies in hemophilia A and an update on its development non-viral genetic medicine platform. In mouse studies, rapid enzymatic synthesis (RES)-derived ceDNA delivered by ctLNP generated peak mean human factor VIII expression of 205% Full story available on Benzinga.com

Generation Bio Co (NASDAQ: GBIO) provided an update on factor VIII expression from a series of mouse and companion non-human primate (NHP) studies in hemophilia A and an update on its development n

CAMBRIDGE, MASS., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, today

Innovations in closed-ended DNA (ceDNA) and cell-targeted lipid nanoparticle (ctLNP) production processes generated peak mean of 205% normal human factor VIII expression in mice Non-human primates (NHPs) demonstrated up to 2% normal human factor VIII expression, and higher-than-expected variability within and between studies Company is using insights from preclinical studies to advance additional novel proprietary … The post Generation Bio Provides Update on Preclinical Studies for Hemophilia A Program appeared first on ForexTV .

Generation Bio Co. (NASDAQ:GBIO) gapped up before the market opened on Friday . The stock had previously closed at $14.20, but opened at $14.87. Generation Bio shares last traded at $14.15, with a volume of 220 shares changing hands. Separately, Zacks Investment Research upgraded shares of Generation Bio from a sell rating to a hold []

Los Angeles, USA, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Phenylketonuria Pipeline Shows Rapid Progress in Clinical Trials | DelveInsight There are approximately 15+ key companies developing the Phenylketonuria therapies. In the upcoming years, many new products such as CNSA-001/PTC923 (PTC Therapeutics), HMI-102 (Homology Medicines), and SYNB1618 (Synlogic) are also expected to enter the Phenylketonuria market. PTC-923 is expected to be the most promising drug among all the upcoming therapies. DelveInsight''s " Phenylketonuria Pipeline Insight " report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in the Phenylketonuria pipeline landscapes. It comprises Phenylketonuria pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Phenylketonuria therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Phenylketonuria pipeline products. Some of the key takeaways from the Phenylketonuria Pipeline Report Major companies such as Synlogic, Homology Medicines, PTC therapeutics, Rubius Therapeutics, NestlÃ, BioMarin, SOM Biotech, Evox Therapeutics, Moderna Therapeutics, Orpharma, Generation Bio, Erydel, Janana therapeutics, American gene technologies, Applied Pharma Research and others are developing potential drug candidates to improve the Phenylketonuria treatment scenario.

Generation Bio Co. (NASDAQ:GBIO)s share price reached a new 52-week low during trading on Friday . The stock traded as low as $17.62 and last traded at $17.62, with a volume of 1070 shares changing hands. The stock had previously closed at $18.69. Separately, Zacks Investment Research raised Generation Bio from a sell rating to []

Generation Bio Co. (NASDAQ:GBIO) reached a new 52-week low during trading on Friday . The company traded as low as $17.62 and last traded at $17.62, with a volume of 1070 shares traded. The stock had previously closed at $18.69. Separately, Zacks Investment Research upgraded Generation Bio from a sell rating to a hold rating []

Generation Bio Co. (NASDAQ:GBIO) shares reached a new 52-week low during mid-day trading on Friday . The company traded as low as $17.62 and last traded at $17.62, with a volume of 1070 shares changing hands. The stock had previously closed at $18.69. Separately, Zacks Investment Research upgraded Generation Bio from a sell rating to []